| Trial ID: | L7227 |
| Source ID: | NCT05377333
|
| Associated Drug: |
Ly3457263
|
| Title: |
A Study of LY3457263 Alone and in Combination With Dulaglutide (LY2189265) in Participants With Type 2 Diabetes
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: LY3457263|DRUG: Placebo|DRUG: Dulaglutide
|
| Outcome Measures: |
Primary: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration, A summary of TEAEs, SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module, Predose up to 16 weeks | Secondary: PK: Area Under the Concentration Versus Time Curve (AUC) of LY3457263, PK: AUC of LY3457263, Pre-dose on Day 1 up to 85 days post-dose
|
| Sponsor/Collaborators: |
Sponsor: Eli Lilly and Company
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
94
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: BASIC_SCIENCE
|
| Start Date: |
2022-06-02
|
| Completion Date: |
2023-11-22
|
| Results First Posted: |
|
| Last Update Posted: |
2024-01-11
|
| Locations: |
Pinnacle Research Group, LLC, Anniston, Alabama, 36207, United States|CenExel ACT, Anaheim, California, 92801, United States|Qps-Mra, Llc, South Miami, Florida, 33143, United States|Atlanta Center of Medical Research, Atlanta, Georgia, 30331 2012, United States|CenExel-HRI, Berlin, New Jersey, 08009, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT05377333
|
